natgillin/translations-raw huggingface dataset:
Tablet core: mannitol (E421), dibasic calcium phosphate, sodium starch glycolate, hydroxypropyl-cellulose (E463), magnesium stearate (E470b) 
Jedro manitol (E421) kalcijev hidrogenfosfat magnezijev stearat (E470b) natrijev karboksimetilškrob hidroksipropil-celuloza (E463)
• other medicines such as ketoconazole (used to treat fungal infections), clarithromycin (used to treat bacterial infections), nefazodone, (an antidepressant), ritonavir and atazanavir (used to treat HIV infection and AIDS), cisapride (used to treat heartburn), ergot alkaloids (used to treat migraines and headaches). 
• druga zdravila, npr. ketokonazol (uporablja se za zdravljenje glivičnih okužb), klaritromicin (uporablja se za zdravljenje bakterijskih okužb), nefazodon (antidepresiv), ritonavir in atazanavir (uporabljata se za zdravljenje okužbe s HIV in aidsa), cisaprid (uporablja se za zdravljenje zgage), alkaloidi ergot (uporabljajo se za zdravljenje migrene in glavobolov).
Due to observations of mostly asymptomatic ventricular pauses and bradycardia, caution should be exercised when administering Possia concomitantly with medicinal products known to induce bradycardia (see section 4.4). 
Zdravila, za katera je znano, da povzročajo bradikardijo Zaradi pojavljanja ventrikularnih pavz in bradikardije, ki so večinoma asimptomatske, je previdnost potrebna pri uporabi zdravila Possia sočasno z zdravili, za katera je znano, da povzročajo bradikardijo (glejte poglavje 4.4).
Ticagrelor is primarily a CYP3A4 substrate and a mild inhibitor of CYP3A4. 
Tikagrelor je v prvi vrsti substrat CYP3A4 in blago zavira CYP3A4.
Your doctor may want you to stop taking Possia 7 
Zdravnik vam bo morda naročil, da 7 dni pred operacijo nehate jemati zdravilo Possia.
However, due to potential pharmacodynamic interactions, caution should be exercised with the concomitant administration of Possia with medicinal products known to alter haemostasis (see section 4.4). 
Toda zaradi možnih farmakodinamičnih medsebojnih delovanj je med sočasno uporabo zdravila Possia in zdravil, ki vplivajo na hemostazo, potrebna previdnost (glejte poglavje 4.4).
Exposure to ticagrelor and the active metabolite were approximately 20% lower in patients with severe renal impairment (creatinine clearance <30 ml/min) compared to subjects with normal renal function 
Izpostavljenost tikagrelorju in njegovemu aktivnemu presnovku je bila pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) približno 20 % manjša kot pri osebah z normalnim delovanjem ledvic (glejte poglavje 4.2).
Higher exposures to ticagrelor (approximately 25% for both Cmax and AUC) and the active metabolite were observed in elderly (≥ 75years) ACS patients compared to younger patients by the population pharmacokinetic analysis. 
Pri starejših osebah (≥ 75 let) z ACS so v primerjavi z mlajšimi s populacijsko farmakokinetično analizo ugotovili večjo izpostavljenost tikagrelorju (približno 25 % za Cmax in AUC) in njegovemu aktivnemu presnovku.
• calendar blisters (with sun/moon symbols) in cartons of 14, 56 and 168 tablets 
• koledarski pretisni omoti (s simboloma sonce/mesec) v škatlah po 14, 56 in 168 tablet.
Other strong inhibitors of CYP3A4 (clarithromycin, nefazodone, ritonavir, and atazanavir) would be expected to have similar effects and their concomitant use with Possia is contraindicated (see section 4.3 and 4.4). 
Pričakovati je mogoče, da drugi močni zaviralci CYP3A4 (klaritromicin, nefazadon, ritonavir ali atanazavir) vplivajo podobno, zato je njihova sočasna uporaba z zdravilom Possia kontraindicirana (glejte poglavji 4.3 in 4.4).
Your doctor will tell you how much to take (usually between 
Zdravnik vam bo povedal, koliko zdravila morate jemati (po navadi med 75 in 150 mg na dan).
If clinically indicated, medicinal products that alter haemostasis should be used with caution in combination with Possia (see section 4.4). 
Če so klinično indicirana zdravila, ki vplivajo na hemostazo, jih je treba v kombinaciji z zdravilom Possia uporabljati previdno (glejte poglavje 4.4).
• PVC-PVDC/Al perforated unit dose transparent blister of 10 tablets; cartons of 100x1 tablets (10 blisters). 
• Prosojen perforiran pretisni omot za enkratni odmerek iz PVC-PVDC/Al z 10 tabletami; škatle s 100x1 tableto (10 pretisnih omotov) .
For Possia, 0.9% of patients discontinued study drug because of dyspnoea compared with 0.1% taking clopidogrel. 
Zaradi dispneje je zdravljenje z raziskovanim zdravilom prekinilo 0,9 % bolnikov, zdravljenje s klopidogrelom pa 0,1 % bolnikov.
This reduces the chance of a blood clot forming that can 
Tako se zmanjša verjetnost nastanka krvnega strdka, ki lahko zmanjša pretok krvi.
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH 
A. IZDELOVALCI, ODGOVORNI ZA SPROŠČANJE SERIJ
• Feeling or being sick 
• omotica ali vrtoglavica
Most reported symptoms of dyspnoea were mild to moderate in intensity, and most were reported as a single episode 
Večina opisanih simptomov z dispnejo je bila blagih do zmernih, in večina jih je bila zabeleženih kot enkraten pojav zgodaj po začetku zdravljenja.
Respiratory, thoracic and mediastinal disorders e, Haemorrhoidal 
Bolezni dihal, prsnega koša in mediastinalnega prostora dispnejac, epistaksa
Bleeding of many different kinds can be increased, for example: 
Opredelitve kategorij krvavitev:
• PVC-PVDC/Al transparent blister (with sun/moon symbols) of 10 tablets; cartons of 60 tablets (6 blisters) and 180 tablets (18 blisters). 
• Prosojen pretisni omot (s simboloma sonce/mesec) iz PVC-PVDC/Al z 10 tabletami; škatle s 60 tabletami (6 pretisnih omotov) in s 180 tabletami (18 pretisnih omotov).
Switching data 
Podatki o prehodu
No dose adjustment is necessary for patients with renal impairment (see section 5.2). 
Bolnikom z okvaro ledvic odmerka ni treba prilagoditi (glejte poglavje 5.2).
Possia and clopidogrel did not differ in rates of PLATO Major Fatal/Life-threatening bleeding, PLATO total Major bleeding, TIMI Major bleeding, or TIMI Minor bleeding (Table 2). 
Zdravilo Possia in klopidogrel se nista razlikovala po deležih hudih krvavitev s smrtnim izidom/smrtno nevarnih krvavitvah po PLATO, vseh hudih krvavitev po PLATO, hudih krvavitev po TIMI in blagih krvavitev po TIMI (preglednica 2).
- recent surgery (including dental work) - you have a condition that affects blood clotting - recent bleeding from your stomach or gut (such as a stomach ulcer or colon ‘polyps') 
• če imate večje tveganje krvavitev zaradi: - nedavne resne poškodbe - nedavne operacije (vključno z zobozdravstvenimi posegi) - če imate kakšno motnjo strjevanja krvi - nedavne krvavitve v želodcu ali črevesu (npr. iz razjede na želodcu ali "polipov" v debelem
- If you get any side effects, talk to your doctor or pharmacist. 
• Če opazite kateri koli neželeni učinek, se posvetujte s svojim zdravnikom ali s farmacevtom.
Therefore, appropriate clinical and/or laboratory monitoring is recommended when giving narrow therapeutic index P-gp dependent medicinal products like digoxin or cyclosporin concomitantly with Possia (see section 4.4). 
Zato je med sočasno uporabo zdravila Possia in zdravil, ki so odvisna od P-gp in imajo ozek terapevtski indeks (kakršno je digoksin ali ciklosporin), priporočljiv ustrezen klinični in/ali laboratorijski nadzor (glejte poglavje 4.4).
The hyperuricaemia AEs reported were 0.5% for ticagrelor vs. 0.2% for clopidogrel. 
Neželeni učinki hiperurikemije so bili opisani pri 0,5 % s tikagrelorjem in pri 0,2 % s klopidogrelom.
Each film coated tablet contains 90 mg ticagrelor. 
Ena filmsko obložena tableta vsebuje 90 mg tikagrelorja.
6.6 Special precautions for disposal 
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
(95% CI) 
RRRa (%) (95 % IZ)
Uncommon (affects 1 to 10 users in 1,000) 
Občasni (pojavijo se pri 1 do 10 od 1000 bolnikov)
Co-administration of Possia and CYP3A4 substrates with narrow therapeutic indices (i.e., cisapride and ergot alkaloids) is not recommended, as ticagrelor may increase the exposure to these medicinal products (see section 4.5). 
Sočasna uporaba zdravila Possia in substratov CYP3A4 z ozkim terapevtskim indeksom (tj. cisaprida in alkaloidov ergot) ni priporočljiva, ker lahko tikagrelor poveča izpostavljenost tem zdravilom (glejte poglavje 4.5).
In patients with stable coronary artery disease on ASA, ticagrelor demonstrates a rapid onset of pharmacological effect as demonstrated by a mean Inhibition of Platelet Aggregation (IPA) for ticagrelor at 0.5 hours after 180 mg loading dose of about 41%, with the maximum IPA effect of 89% by 2-4 hours post dose, and maintained between 2-8 hours. 
To se kaže s povprečno 41 % zavrtjem agregacije trombocitov (IPAInhibition of Patelet Aggregation) 0,5 ure po 180-mg polnilnem odmerku tikagrelorja in največjim učinkom IPA 89 % v 2 do 4 urah po odmerku in se ohrani od 2 do 8 ur.
• selective serotonin reuptake inhibitors (abbreviated as SSRIs) taken as antidepressants such as paroxetine, sertraline and citalopram 
• selektivne zaviralce prevzema serotonina (s kratico: SSRI), ki se uporabljajo kot antidepresivi,
Co-administration of Possia and CYP3A4 substrates with narrow therapeutic indices (i.e., cisapride or ergot alkaloids) is not recommended, as ticagrelor may increase the exposure to these medicinal products (see section 4.4). 
Sočasna uporaba zdravila Possia in substratov CYP3A4 z ozkim terapevtskim indeksom (tj. cisaprida ali alkaloidov ergot) ni priporočljiva, ker tikagrelor lahko poveča izpostavljenost tem zdravilom (glejte poglavje 4.4).
• Rash 
• srbenje
Detailed information on this medicinal product is available on the website of the European Medicines 
DATUM ZADNJE REVIZIJE BESEDILA Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA) http://www.ema.europa.eu
- bleeding after surgery or from cuts and wounds that is more than normal (common) - bleeding from your stomach lining (ulcer) (uncommon). 
- krvavitev po operaciji ali krvavitev iz ureznin ali ran, ki je močnejša kot po navadi (pogosto) - krvavitev iz želodčne sluznice (razjede) (občasno) - krvavitev iz dlesni (občasno) - kri v ušesu (redko) - notranja krvavitev (redko) - krvavitev v sklepe, ki povzroči bolečo oteklino (redko).
What Possia looks like and contents of the pack Film-coated tablet (tablet): The tablets are round, biconvex, yellow, film-coated marked with a “90” 
Filmsko obložena tableta (tableta): Tablete so okrogle, na obeh straneh izbočene, rumene filmsko obložene tablete z oznako "90" nad "T" na eni strani.
Mean serum uric acid concentration increased approximately 15% with ticagrelor compared to approximately 7.5% with clopidogrel and after treatment was stopped, decreased to approximately 7% on ticagrelor but with no decrease observed for clopidogrel. 
Povprečna koncentracija sečne kisline v serumu se je s tikagrelorjem povečala za približno 15 % in s klopidogrelom za približno 7,5 %.
SRI = serious recurrent ischaemia; RI = recurrent ischaemia; TIA = transient ischaemic attack; ATE = arterial thrombotic event. 
Negativno RRR pomeni povečanje relativnega tveganja izključujoč nemi miokardni infarkt RPI = resna ponovna ishemija, PI = ponovna ishemija, TIA = tranzitorna ishemična ataka, ATD = arterijski trombotični dogodek.
Due to observations of mostly asymptomatic ventricular pauses in an earlier clinical study, patients with an increased risk of bradycardic events (e.g. patients without a pacemaker who have sick sinus syndrome, 2nd or 3rd degree AV block or bradycardic-related syncope) were excluded from the main PLATO study evaluating the safety and efficacy of Possia. 
V glavno PLATO študijo varnosti in učinkovitosti zdravila Possia niso bili vključeni bolniki s tveganjem bradikardnih dogodkov (npr. bolniki brez srčnega spodbujevalnika in z boleznijo sinusnega vozla, AV-blokom 2. ali 3. stopnje ali sinkopo zaradi bradikardije).
However, more PLATO combined Major + Minor bleeding occurred with ticagrelor compared with clopidogrel. 
Med uporabo tikagrelorja pa se je pojavilo več hudih + blagih krvavitev po PLATO kot med uporabo klopidogrela.
Possia 90 mg film-coated tablets ticagrelor 
Possia 90 mg filmsko obložene tablete tikagrelor
No data are available on concomitant use of Possia with potent P-gp inhibitors (e.g. verapamil, quinidine, cyclosporin) that may increase ticagrelor exposure. 
Podatkov o sočasni uporabi zdravila Possia z močnimi zaviralci P-gp (npr. z verapamilom, kinidinom, ciklosporinom), ki lahko povečajo izpostavljenost tikagrelorju, ni.
Keep this medicine out of the reach and sight of children. 
Zdravilo shranjujte nedosegljivo otrokom!
No dose adjustment is necessary for patients with mild hepatic impairment. 
Bolnikom z blago okvaro jeter odmerka ni treba prilagoditi.
Co-administration of Possia with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir) is contraindicated (see section 4.3 and 4.5). 
Sočasna uporaba zdravila Possia z močnimi zaviralci CYP3A4 (npr. s ketokonazolom, klaritromicinom, nefazodonom, ritonavirjem in atazanavirjem) je kontraindicirana (glejte poglavji 4.3 in 4.5).
Co-administration of ticagrelor with strong CYP3A4 inducers (e.g. rifampicin, dexamethasone, phenytoin, carbamazepine and phenobarbital) is discouraged, as co-administration may lead to a decrease in exposure and efficacy of ticagrelor (see section 4.5). 
Tikagrelorja ni priporočljivo uporabljati sočasno z močnimi induktorji CYP3A4 (npr. rifampicinom, deksametazonom, fenitoinom, karbamazepinom in fenobarbitalom), ker lahko sočasna uporaba zmanjša izpostavljenost tikagrelorju in njegovo učinkovitost (glejte poglavje 4.5).
Renal function should be checked after one month and thereafter according to routine medical practice, paying special attention to patients ≥ 75 years, patients with moderate/severe renal impairment and those receiving concomitant treatment with an ARB. 
Posebno pozornost je treba nameniti bolnikom, starim ≥ 75 let, bolnikom z zmerno/hudo okvaro ledvic in tistim, ki sočasno prejemajo zaviralce receptorjev angiotenzina.
Possia helps stop the clumping of platelets. 
Zdravilo Possia pomaga preprečiti sprijemanje trombocitov.
Co-administration of Possia with tolbutamide resulted in no change in the plasma levels of either medicinal product, which suggest that ticagrelor is not a CYP2C9 inhibitor and unlikely to alter the CYP2C9 mediated metabolism of medicinal products like warfarin and tolbutamide. 
To kaže, da tikagrelor ne zavira CYP2C9 in tako ni verjetno, da bi spremenil presnovo drugih zdravil, npr. varfarina in tolbutamida, s CYP2C9.
Taking Possia with food and drink 
Jemanje zdravila Possia skupaj s hrano in pijačo Zdravilo Possia lahko vzamete s hrano ali brez nje.
During the Holter substudy in PLATO, more patients had ventricular pauses >3 seconds with ticagrelor than with clopidogrel during the acute phase of their ACS. 
V holterski podštudiji PLATO je imelo med akutno fazo ACS ventrikularne pavze, ≥3 sekund, več bolnikov, ki so dobivali tikagrelor, kot bolnikov, ki so dobivali klopidogrel.
• You are taking any of the following medicines: ketoconazole (used to treat fungal infections), clarithromycin (used to treat bacterial infections), nefazodone (an antidepressant), ritonavir and atazanavir (used to treat HIV infection and AIDS). 
klaritromicin (uporablja se za zdravljenje bakterijskih okužb), nefazodon (antidepresiv), ritonavir in atazanavir (uporabljata se za zdravljenje okužbe s HIV in aidsa).
The increase in ventricular pauses in the acute phase of ACS was more pronounced in ticagrelor patients with history of CHF (9.2% versus 5.4% in patients without CHF history; for clopidogrel patients, 4.0% in those with versus 3.6% in those without CHF history) This imbalance did not occur at one month: 2.0% versus 2.1% for ticagrelor patients with and without CHF history respectively; and 3.8% versus 1.4% with clopidogrel. 
Porast ventrikularnih pavz v akutni fazi ACS je bil izrazitejši pri bolnikih, ki so dobivali tikagrelor in so imeli anamnezo kongestivnega srčnega popuščanja (9,2 % v primerjavi s 5,4 % med bolniki brez takšne anamneze; pri bolnikih, ki so dobivali klopidogrel, 4,0 % pri tistih z anamnezo kongestivnega srčnega popuščanja in 3,6 % pri tistih brez takšne anamneze.
On a background of daily ASA, ticagrelor 90 mg twice daily showed superiority to 75 mg daily clopidogrel in preventing the composite endpoint of cardiovascular [CV] death, myocardial infarction [MI], or stroke, with the difference driven by CV death and MI. 
Ob vsakodnevnem jemanju ASA je bil tikagrelor v odmerku 90 mg dvakrat na dan superioren od 75 mg klopidogrela na dan pri preprečevanju sestavljenega opazovanega dogodka (kardiovaskularna [KV] smrt, miokardni infarkt [MI] ali možganska kap), pri čemer sta bila glavna dejavnika razlike KV smrt in MI. Bolniki so dobili 300-mg polnilni odmerek klopidogrela (600-mg odmerek je bil možen v primeru PCI) ali 180 mg tikagrelorja.
Possia 90 mg tablets ticagrelor 
IME ZDRAVILA Possia 90 mg tablete tikagrelor
No data are available on concomitant use of Possia with potent P-glycoprotein (P-gp) inhibitors (e.g. verapamil, quinidine, cyclosporin) that may increase ticagrelor exposure. 
Podatkov o sočasni uporabi zdravila Possia z močnimi zaviralci P-glikoproteina (P-gp) (npr. z verapamilom, kinidinom, ciklosporinom), ki lahko povečajo izpostavljenost tikagrelorju, ni.
The safety of Possia in patients with acute coronary syndromes (UA, NSTEMI and STEMI) was evaluated in the pivotal large phase 3 PLATO ([PLATelet Inhibition and Patient Outcomes] study, 18,624 patients), which compared patients treated with Possia (loading dose of 180 mg of Possia and a maintenance dose of 90 mg twice daily) to patients treated with clopidogrel (300-600 mg loading dose followed by 75 mg once daily maintenance dose) both given in combination with acetylsalicylic acid (ASA) and other standard therapies. 
Primerjala je bolnike, zdravljene z zdravilom Possia (polnilni odmerek 180 mg in vzdrževalni odmerek 90 mg dvakrat na dan), in bolnike, zdravljene s klopidogrelom (polnilni odmerek od 300 do 600 mg in potem vzdrževalni odmerek 75 mg enkrat na dan).
As a precautionary measure, the use of ticagrelor in patients with uric acid nephropathy is discouraged. 
Iz previdnosti zato tikagrelorja ni priporočljivo uporabljati pri bolnikih z urično nefropatijo.
Detailed information on this medicine is available on the European Medicines Agency web site: 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
Higher exposures to ticagrelor and the active metabolite were observed in women compared to men. 
Pri ženskah so v primerjavi z moškimi ugotovili večjo izpostavljenost tikagrelorju in njegovemu aktivnemu presnovku.
However no evidence of clinically significant adverse reactions was observed in the PLATO trial after concomitant administration with one or more medicinal products known to induce bradycardia (e.g., 96% beta blockers, 33% calcium channel blockers diltiazem and verapamil, and 4% digoxin) (see section 4.5). 
Vendar pa v preskušanju PLATO po sočasni uporabi z enim ali več zdravili, za katera je znano, da povzročajo bradikardijo (npr. 96 % zaviralci adrenergičnih receptorjev beta, 33 % zaviralca kalcijevih kanalčkov diltiazem in verapamil ter 4 % digoksin) niso ugotovili klinično pomembnih neželenih učinkov (glejte poglavje 4.5).
Of these AEs 0.05% for ticagrelor vs. 0.02% for clopidogrel were considered causally related by investigators. 
Od teh neželenih učinkov so raziskovalci kot vzročno povezane ocenili 0,05 % pri tikagrelorju in 0,02 % pri klopidogrelu.
No clinically relevant effect on oral contraceptive efficacy is expected when levonorgestrel and ethinyl estradiol are 
Med sočasno uporabo levonorgestrela in etinilestradiola z zdravilom Possia ni pričakovati klinično pomembnega vpliva na učinkovitost peroralnih kontraceptivov.
However no evidence of clinically significant adverse reactions was observed in the PLATO trial after concomitant administration with one or more medicinal products known to induce bradycardia (e.g., 96% beta blockers, 33% calcium channel blockers diltiazem and verapamil, and 4% digoxin). 
Vendar pa v preskušanju PLATO po sočasni uporabi z enim ali več zdravili, za katera je znano, da povzročajo bradikardijo (npr. 96 % zaviralci adrenergičnih receptorjev beta, 33 % zaviralca kalcijevih kanalčkov diltiazem in verapamil ter 4 % digoksin) niso ugotovili klinično pomembnih neželenih učinkov.
Table 2 -Kaplan-Meier estimate of bleeding rates by treatment 
Kaplan-Meierjeva ocena deleža krvavitev glede na zdravilo Possia (%/leto) n = 9235
- This medicine has been prescribed for you only. 
• Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
Confusion b, 
Preglednica 2.
Caution should be exercised when administering ticagrelor to patients with history of hyperuricaemia or gouty arthritis. 
Pri bolnikih z anamnezo hiperurikemije ali uričnega artritisa je treba tikagrelor uporabljati previdno.
• non-steroidal anti-inflammatory drugs (abbreviated as NSAIDs) often taken as pain killers such as ibuprofen and naproxen. 
• nesteroidna protivnetna zdravila (s kratico: NSAID), ki se pogosto uporabljajo proti bolečinam,
• Diarrhoea or indigestion 
• slabost v želodcu ali bruhanje
See a doctor straight away if you notice any of the following - you may need urgent medical 
Če opazite kaj od naslednjega, nemudoma pojdite do zdravnika.
Possia contains ticagrelor a member of the chemical class cyclopentyltriazolopyrimidines (CPTP), which is a selective adenosine diphosphate (ADP) receptor antagonist acting on the P2Y12 
Zdravilo Possia vsebuje tikagrelor, učinkovino iz kemične skupine ciklopentiltriazolopirimidinov (CPTP).
Ticagrelor is a mild CYP3A4 inhibitor. 
Tikagrelor blago zavira CYP3A4.
Paraesthesia 
Dispneja
Wound haemorrhage, Traumatic haemorrhage 
Ušesne bolezni, vključno z motnjami labirinta ušesna krvavitev, vrtoglavica
The superiority of ticagrelor over clopidogrel in reducing major CV events was not significantly affected by patient CYP2C19 or ABCB1 genotype. 
Genotip CYP2C19 ali ABCB1 ni bistveno vplival na superiornost tikagrelorja v primerjavi s klopidogrelom za zmanjšanje hudih KV dogodkov.
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
A. IZDELOVALCI, ODGOVORNI ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE
Hyperuricaemia, Blood uric acid increased 
Bolezni prebavil gastrointestinalna krvavitevd hematemeza,
Ticagrelor is well tolerated in single doses up to 900 mg. Gastrointestinal toxicity was dose-limiting in a single ascending dose study. 
Bolniki tikagrelor dobro prenašajo v enkratnih odmerkih do 900 mg.
Biotransformation 
FARMACEVTSKA OBLIKA
Ask your doctor or pharmacist for advice before taking any medicine, if you are pregnant or breast 
Če ste noseči ali dojite, se posvetujte s svojim zdravnikom ali s farmacevtom, preden vzamete katerokoli zdravilo.
Ticagrelor has not been studied in patients with moderate or severe hepatic impairment and its use in these patients is contraindicated 
Tikagrelor ni raziskan pri bolnikih z zmerno ali hudo okvaro jeter in njegova uporaba pri teh bolnikih je kontraindicirana (glejte poglavji 4.3 in 4.4).
ARR 
Dojenje